((Automated translation by Reuters, please see disclaimer https://bit.ly/rtrsauto))
(Recast with details throughout the article)
Switzerland’s Roche ROG.S will acquire U.S. biopharmaceutical company Poseida Therapeutics PSTX.O in an all-cash deal worth up to $1.5 billion, the two companies announced Tuesday.
Poseida will be purchased for $9 per share in cash, and shareholders will also receive a non-negotiable contingent value right of up to $4 per share if specific milestones are met, bringing the value of the deal to approximately $1 .5 billion dollars.
The transaction should be finalized during the first quarter of 2025.
“We have worked closely with Roche in our hematologic malignancies collaboration, and we are excited to join Roche to work together as colleagues on our pipeline and future programs,” said Kristin Yarema, President and CEO. CEO of Poseida, based in San Diego, in a statement.
Poseida and his employees will join Roche as part of the Swiss company’s pharmaceutical division, Poseida said.
The acquisition will provide Roche with new allogeneic cell therapy capability, with opportunities focused on CAR-T programs covered by Poseida’s existing collaboration with Roche in hematologic malignancies, the company said. American company.
It will include CAR-T programs for solid tumors and autoimmune diseases, as well as Poseida’s genetic engineering platform and related preclinical medicines, she added.
Business
Related News :